AdiuTide Pharmaceuticals GmbH

AdiuTide Pharmaceuticals GmbH is a biopharmaceutical company, which discovers and develops novel nucleic acid-based therapeutics to treat a number of diseases, including cancer, infectious diseases, asthma and allergies, and for use as vaccine adjuvant. The Company has established a broad IP position based on immune stimulatory oligonucleotides, in particular Toll-like Receptor 9 (TLR9) Agonists and Retinoic Acid-Inducible Gene I (RIG-I) ligands.